Medtronic: Now Is The Time To Buy This Deep Value Dividend Aristocrat


  • When done right, pairing quality and value can be an especially potent investing strategy.
  • Medtronic’s revenue edged higher as currency-neutral non-GAAP EPS dipped a bit in the fiscal fourth quarter.
  • Relative to its size, the company’s $17 billion in net debt is quite manageable.
  • MDT stock could be nearly 20% undervalued from the current share price.
  • The MedTech company could be positioned for 45%+ cumulative total returns through fiscal year 2027.

Team of surgeons operating on patient in hospital

A team of surgeons operate on a patient in the operating room.


Centering my portfolio around high-quality dividend stocks, I tend to be very much in tune with the get rich slowly mindset.

This is because, in my view, the speculation

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MDT, UNH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *